Skip to main content

Advertisement

SpringerLink
Log in

Soluble interleukin-2 receptor level on day 7 as a predictor of graft-versus-host disease after HLA-haploidentical stem cell transplantation using reduced-intensity conditioning

  • Original Article
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

In the present study, we analyzed the kinetics of serum soluble interleukin-2 receptor (sIL-2R) using data from 77 patients undergoing HLA-haploidentical transplantation using reduced-intensity conditioning (RIC), who were at an advanced stage or at high risk for relapse, to clarify the usefulness of sIL-2R as a biomarker of acute graft-versus-host disease (GVHD). Anti-T-lymphocyte globulin and methylprednisolone were used as GVHD prophylaxis. While the median sIL-2R in 38 patients not developing GVHD was suppressed at levels <740 U/ml, sIL-2R in 25 patients developing severe GVHD peaked on day 11 (1,663 U/ml), and thereafter decreased to <1,000 U/ml after day 30. The occurrence of GVHD was not limited to times of high sIL-2R level, but occurred at any time point on the sIL-2R curve. Most patients developing GVHD, however, experienced a higher sIL-2R level early in their transplant course. The combination of RIC and glucocorticoids sufficiently suppressed sIL-2R levels after HLA-haploidentical transplantation. In a multivariate analysis to identify factors associated with GVHD, day 7 sIL-2R >810 U/ml was the only factor significantly associated with the occurrence of severe GVHD (p = 0.0101).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Armitage JO. Medical progress. Bone marrow transplantation. N Engl J Med. 1994;330:827–38.

    Article  PubMed  CAS  Google Scholar 

  2. Aversa F, Terenzi A, Tabilio A, Falzetti F, Carotti A, Ballanti S, et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol. 2005;23:3447–54.

    Article  PubMed  Google Scholar 

  3. Di Ianni M, Falzetti F, Carotti A, Terenzi A, Castellino F, Bonifacio E, et al. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood. 2011;117:3921–8.

    Article  PubMed  CAS  Google Scholar 

  4. Lu DP, Dong L, Wu T, Huang XJ, Zhang MJ, Han W, et al. Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood. 2006;107:3065–73.

    Article  PubMed  CAS  Google Scholar 

  5. Ogawa H, Ikegame K, Kaida K, Yoshihara S, Fujioka T, Taniguchi Y, et al. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) bone marrow transplantation using only pharmacological GVHD prophylaxis. Exp Hematol. 2008;36:1–8.

    Article  PubMed  CAS  Google Scholar 

  6. Brunstein CG, Fuchs EJ, Carter SL, Karanes C, Costa LJ, Wu J, et al. Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. Blood. 2011;118:282–8.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  7. Lee KH, Lee JH, Lee JH, Kim DY, Seol M, Lee YS, et al. Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome. Blood. 2011;118:2609–17.

    Article  PubMed  CAS  Google Scholar 

  8. Diamantstein T, Osawa H. The interleukin-2 receptor, its physiology and a new approach to a selective immunosuppressive therapy by anti-interleukin-2 receptor monoclonal antigen. Immunol Rev. 1986;92:5–27.

    Article  PubMed  CAS  Google Scholar 

  9. Minami Y, Kono T, Miyazaki T, Taniguchi T. The IL-2 receptor complex: its structure, function and target genes. Annu Rev Immunol. 1993;11:245–68.

    Article  PubMed  CAS  Google Scholar 

  10. Junghans RP, Waldmann TA. Metabolism of Tac (IL2Ralpha): physiology of cell surface shedding and renal catabolism, and suppression of catabolism by antibody binding. J Exp Med. 1996;183:1587–602.

    Article  PubMed  CAS  Google Scholar 

  11. Robb RJ, Kutny RM. Structure-function relationships for the IL 2-receptor system. IV. Analysis of the sequence and ligand-binding properties of soluble Tac protein. J Immunol. 1987;139:855–62.

    PubMed  CAS  Google Scholar 

  12. Paczesny S, Krijanovski OI, Braun TM, Choi SW, Clouthier SG, Kuick R, et al. A biomarker panel for acute graft-versus-host disease. Blood. 2009;113:273–8.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  13. Siegert W, Josimovic-Alasevic O, Schwerdtfeger R, Baurmann H, Schmidt CA, Musch R, et al. Soluble interleukin-2 receptors in patients after bone marrow transplantation. Bone Marrow Transpl. 1990;6:97–101.

    CAS  Google Scholar 

  14. Miyamoto T, Akashi K, Hayashi S, Gondo H, Murakawa M, Tanimoto K, et al. Serum concentration of the soluble interleukin-2 receptor for monitoring acute graft-versus-host disease. Bone Marrow Transpl. 1996;17:185–90.

    CAS  Google Scholar 

  15. Foley R, Couban S, Walker I, Greene K, Chen CS, Messner H, et al. Monitoring soluble interleukin-2 receptor levels in related and unrelated donor allogeneic bone marrow transplantation. Bone Marrow Transpl. 1998;21:769–73.

    Article  CAS  Google Scholar 

  16. Grimm J, Zeller W, Zander AR. Soluble interleukin-2 receptor serum levels after allogeneic bone marrow transplantation as a marker for GVHD. Bone Marrow Transpl. 1998;21:29–32.

    Article  CAS  Google Scholar 

  17. Kami M, Matsumura T, Tanaka Y, Mikami Y, Miyakoshi S, Ueyama J, et al. Serum levels of soluble interleukin-2 receptor after bone marrow transplantation: a true marker of acute graft-versus-host disease. Leuk Lymphoma. 2000;38:533–40.

    Article  PubMed  CAS  Google Scholar 

  18. Ogawa H, Ikegame K, Soma T, Kawakami M, Tsuboi A, Kim EH, et al. Powerful graft-versus-leukemia effects exerted by HLA-haploidentical grafts engrafted with a reduced-intensity regimen for relapse following myeloablative HLA-matched transplantation. Transplantation. 2004;78:488–9.

    Article  PubMed  Google Scholar 

  19. Ikegame K, Kawakami M, Yamagami T, Maeda H, Onishi K, Taniguchi Y, et al. HLA-haploidentical nonmyeloablative stem cell transplantation: induction to tolerance without passing through mixed chimerism. Clin Lab Haematol. 2005;27:1–3.

    Article  Google Scholar 

  20. Lee KH, Lee JH, Lee JH, Kim DY, Kim SH, Shin HJ, et al. Hematopoietic cell transplantation from an HLA-mismatched familial donor is feasible without ex vivo-T cell depletion after reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin. Biol Blood Marrow Transpl. 2009;15:61–72.

    Article  CAS  Google Scholar 

  21. Perkins JD, Nelson DL, Rakela J, Grambsch PM, Krom RA, et al. Soluble interleukin-2 receptor level as an indicator of liver allograft rejection. Transplantation. 1989;47:77–81.

    Article  PubMed  CAS  Google Scholar 

  22. Kamihira S, Atogami S, Sohda H, Momita S, Yamada Y, Tomonaga M. Significance of soluble interleukin-2 receptor levels for evaluation of the progression of adult T-cell leukemia. Cancer. 1994;73:2753–8.

    Article  PubMed  CAS  Google Scholar 

  23. Kalmanti M, Karamolengou K, Dimitriou H, Tosca A, Vlachonikolis I, Peraki M, et al. Serum levels of tumor necrosis factor and soluble interleukin 2 receptor as markers of disease activity and prognosis in childhood leukemia and lymphoma. Int J Hematol. 1993;57:147–52.

    PubMed  CAS  Google Scholar 

  24. Pui CH, Ip SH, Iflah S, Behm FG, Grose BH, Dodge RK, et al. Serum interleukin 2 receptor levels in childhood acute lymphoblastic leukemia. Blood. 1988;71:1135–7.

    PubMed  CAS  Google Scholar 

  25. Cimino G, Amadori S, Cava MC, De Sanctis V, Petti MC, Di Gregorio AO, et al. Serum interleukin-2 (IL-2), soluble IL-2 receptors and tumor necrosis factor-alfa levels are significantly increased in acute myeloid leukemia patients. Leukemia. 1991;5:32–5.

    PubMed  CAS  Google Scholar 

  26. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, et al. Clinical manifestations of graft-versus-host diseases in human recipients of marrow from HLA matched sibling donors. Transplantation. 1974;18:295–304.

    Article  PubMed  CAS  Google Scholar 

  27. Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transpl. 2013;48:452–8.

    Article  CAS  Google Scholar 

  28. Kanda J, Atsuta Y, Wake A, Ichinohe T, Takanashi M, Morishima Y, et al. Impact of the direction of HLA mismatch on transplantation outcomes in single unrelated cord blood transplantation. Biol Blood Marrow Transpl. 2013;19:247–54.

    Article  Google Scholar 

  29. Ferrara JL, Harris AC, Greenson JK, Braun TM, Holler E, Teshima T, et al. Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease. Blood. 2011;118:6702–8.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  30. Paczesny S, Braun TM, Levine JE, Hogan J, Crawford J, Coffing B, et al. Elafin is a biomarker of graft-versus-host disease of the skin. Sci Transl Med. 2010;2:13ra2.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  31. Paczesny S, Raiker N, Brooks S, Mumaw C. Graft-versus-host disease biomarkers: omics and personalized medicine. Int J Hematol. 2013;98:275–92.

    Article  PubMed  CAS  Google Scholar 

  32. Ferrara JL, Levy R, Chao NJ. Pathophysiology mechanism of acute graft-vs.-host disease [review]. Biol Blood Marrow Transpl. 1999;5:347–56.

    Article  CAS  Google Scholar 

Download references

Acknowledgments

We thank the medical, nursing, and laboratory staff of the participating departments for their contributions.

Conflict of interest

The authors declare no conflict of interest.

Author information

Authors and Affiliations

  1. Division of Hematology, Department of Internal Medicine, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo, 663-8501, Japan

    Katsuji Kaida, Kazuhiro Ikegame, Satoshi Yoshihara, Shinichi Ishii, Masaya Okada, Takayuki Inoue, Hiroya Tamaki, Toshihiro Soma & Hiroyasu Ogawa

  2. Department of Transfusion Medicine, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan

    Junko Ikemoto, Rie Murata, Reiko Irie, Yoshihiro Fujimori & Shunro Kai

Authors
  1. Katsuji Kaida
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kazuhiro Ikegame
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Junko Ikemoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Rie Murata
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Reiko Irie
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Satoshi Yoshihara
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Shinichi Ishii
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Masaya Okada
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Takayuki Inoue
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Hiroya Tamaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Toshihiro Soma
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Yoshihiro Fujimori
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Shunro Kai
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Hiroyasu Ogawa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hiroyasu Ogawa.

Additional information

Katsuji Kaida and Kazuhiro Ikegame contributed equally.

About this article

Cite this article

Kaida, K., Ikegame, K., Ikemoto, J. et al. Soluble interleukin-2 receptor level on day 7 as a predictor of graft-versus-host disease after HLA-haploidentical stem cell transplantation using reduced-intensity conditioning. Int J Hematol 99, 463–470 (2014). https://doi.org/10.1007/s12185-014-1542-x

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-014-1542-x

Keywords

Search

Navigation